Hang Zhou1,2, Christopher T Rentsch2,3,4, Zhongshan Cheng1,2, Rachel L Kember5,6, Yaira Z Nunez1,2, Richard M Sherva7, Janet P Tate2,3, Cecilia Dao2,3, Ke Xu1,2, Renato Polimanti1,2, Lindsay A Farrer7,8,9,10,11, Amy C Justice2,3,12, Henry R Kranzler6,13, Joel Gelernter1,2,14,15. 1. Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut. 2. Department of Psychiatry, Veterans Affairs Connecticut Healthcare System, West Haven. 3. Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. 4. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom. 5. Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia. 6. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania. 7. Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts. 8. Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts. 9. Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts. 10. Department of Neurology, Boston University School of Medicine, Boston, Massachusetts. 11. Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts. 12. Yale School of Public Health, New Haven, Connecticut. 13. Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia. 14. Department of Genetics, Yale University School of Medicine, New Haven, Connecticut. 15. Department of Neuroscience, Yale University School of Medicine, New Haven, Connecticut.
Abstract
Importance: With the current opioid crisis, it is important to improve understanding of the biological mechanisms of opioid use disorder (OUD). Objectives: To detect genetic risk variants for OUD and determine genetic correlations and causal association with OUD and other traits. Design, Setting, and Participants: A genome-wide association study of electronic health record-defined OUD in the Million Veteran Program sample was conducted, comprising 8529 affected European American individuals and 71 200 opioid-exposed European American controls (defined by electronic health record trajectory analysis) and 4032 affected African American individuals and 26 029 opioid-exposed African American controls. Participants were enrolled from January 10, 2011, to May 21, 2018, with electronic health record data for OUD diagnosis from October 1, 1999, to February 7, 2018. Million Veteran Program results and additional OUD case-control genome-wide association study results from the Yale-Penn and Study of Addiction: Genetics and Environment samples were meta-analyzed (total numbers: European American individuals, 10 544 OUD cases and 72 163 opioid-exposed controls; African American individuals, 5212 cases and 26 876 controls). Data on Yale-Penn participants were collected from February 14, 1999, to April 1, 2017, and data on Study of Addiction: Genetics and Environment participants were collected from 1990 to 2007. The key result was replicated in 2 independent cohorts: proxy-phenotype buprenorphine treatment in the UK Biobank and newly genotyped Yale-Penn participants. Genetic correlations between OUD and other traits were tested, and mendelian randomization analysis was conducted to identify potential causal associations. Main Outcomes and Measures: Main outcomes were International Classification of Diseases, Ninth Revision-diagnosed OUD or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision-diagnosed OUD (Million Veteran Program), and DSM-IV-defined opioid dependence (Yale-Penn and Study of Addiction: Genetics and Environment). Results: A total of 114 759 individuals (101 016 men [88%]; mean [SD] age, 60.1 [12.8] years) were included. In 82 707 European American individuals, a functional coding variant (rs1799971, encoding Asn40Asp) in OPRM1 (μ-opioid receptor gene, the main biological target for opioid drugs; OMIM 600018) reached genome-wide significance (G allele: β = -0.066 [SE = 0.012]; P = 1.51 × 10-8). The finding was replicated in 2 independent samples. Single-nucleotide polymorphism-based heritability of OUD was 11.3% (SE = 1.8%). Opioid use disorder was genetically correlated with 83 traits, including multiple substance use traits, psychiatric illnesses, cognitive performance, and others. Mendelian randomization analysis revealed the following associations with OUD: risk of tobacco smoking, depression, neuroticism, worry neuroticism subcluster, and cognitive performance. No genome-wide significant association was detected for African American individuals or in transpopulation meta-analysis. Conclusions and Relevance: This genome-wide meta-analysis identified a significant association of OUD with an OPRM1 variant, which was replicated in 2 independent samples. Post-genome-wide association study analysis revealed associated pleiotropic characteristics. Recruitment of additional individuals with OUD for future studies-especially those of non-European ancestry-is a crucial next step in identifying additional significant risk loci.
Importance: With the current opioid crisis, it is important to improve understanding of the biological mechanisms of opioid use disorder (OUD). Objectives: To detect genetic risk variants for OUD and determine genetic correlations and causal association with OUD and other traits. Design, Setting, and Participants: A genome-wide association study of electronic health record-defined OUD in the Million Veteran Program sample was conducted, comprising 8529 affected European American individuals and 71 200 opioid-exposed European American controls (defined by electronic health record trajectory analysis) and 4032 affected African American individuals and 26 029 opioid-exposed African American controls. Participants were enrolled from January 10, 2011, to May 21, 2018, with electronic health record data for OUD diagnosis from October 1, 1999, to February 7, 2018. Million Veteran Program results and additional OUD case-control genome-wide association study results from the Yale-Penn and Study of Addiction: Genetics and Environment samples were meta-analyzed (total numbers: European American individuals, 10 544 OUD cases and 72 163 opioid-exposed controls; African American individuals, 5212 cases and 26 876 controls). Data on Yale-Penn participants were collected from February 14, 1999, to April 1, 2017, and data on Study of Addiction: Genetics and Environment participants were collected from 1990 to 2007. The key result was replicated in 2 independent cohorts: proxy-phenotype buprenorphine treatment in the UK Biobank and newly genotyped Yale-Penn participants. Genetic correlations between OUD and other traits were tested, and mendelian randomization analysis was conducted to identify potential causal associations. Main Outcomes and Measures: Main outcomes were International Classification of Diseases, Ninth Revision-diagnosed OUD or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision-diagnosed OUD (Million Veteran Program), and DSM-IV-defined opioid dependence (Yale-Penn and Study of Addiction: Genetics and Environment). Results: A total of 114 759 individuals (101 016 men [88%]; mean [SD] age, 60.1 [12.8] years) were included. In 82 707 European American individuals, a functional coding variant (rs1799971, encoding Asn40Asp) in OPRM1 (μ-opioid receptor gene, the main biological target for opioid drugs; OMIM 600018) reached genome-wide significance (G allele: β = -0.066 [SE = 0.012]; P = 1.51 × 10-8). The finding was replicated in 2 independent samples. Single-nucleotide polymorphism-based heritability of OUD was 11.3% (SE = 1.8%). Opioid use disorder was genetically correlated with 83 traits, including multiple substance use traits, psychiatric illnesses, cognitive performance, and others. Mendelian randomization analysis revealed the following associations with OUD: risk of tobacco smoking, depression, neuroticism, worry neuroticism subcluster, and cognitive performance. No genome-wide significant association was detected for African American individuals or in transpopulation meta-analysis. Conclusions and Relevance: This genome-wide meta-analysis identified a significant association of OUD with an OPRM1 variant, which was replicated in 2 independent samples. Post-genome-wide association study analysis revealed associated pleiotropic characteristics. Recruitment of additional individuals with OUD for future studies-especially those of non-European ancestry-is a crucial next step in identifying additional significant risk loci.
Authors: Sarah M C Colbert; Alexander S Hatoum; Andrey Shabalin; Qingqin S Li; Hilary Coon; Elliot C Nelson; Arpana Agrawal; Anna R Docherty; Emma C Johnson Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2021-11-25 Impact factor: 3.568
Authors: D Max Smith; James M Stevenson; Teresa T Ho; Christine M Formea; Roseann S Gammal; Larisa H Cavallari Journal: J Am Coll Clin Pharm Date: 2021-12-19
Authors: Romain Icick; Alexey Shadrin; Børge Holen; Naz Karadag; Aihua Lin; Guy Hindley; Kevin O'Connell; Oleksandr Frei; Shahram Bahrami; Margrethe Collier Høegh; Weiqiu Cheng; Chun C Fan; Srdjan Djurovic; Anders M Dale; Trine Vik Lagerberg; Olav B Smeland; Ole A Andreassen Journal: Neuropsychopharmacology Date: 2022-08-11 Impact factor: 8.294
Authors: Richard Sherva; Congcong Zhu; Leah Wetherill; Howard J Edenberg; Emma Johnson; Louisa Degenhardt; Arpana Agrawal; Nicholas G Martin; Elliot Nelson; Henry R Kranzler; Joel Gelernter; Lindsay A Farrer Journal: Explor Med Date: 2021-02-28
Authors: Chang Shu; David W Sosnowski; Ran Tao; Amy Deep-Soboslay; Joel E Kleinman; Thomas M Hyde; Andrew E Jaffe; Sarven Sabunciyan; Brion S Maher Journal: Drug Alcohol Depend Date: 2021-02-26 Impact factor: 4.492
Authors: Philip D Harvey; Tim B Bigdeli; Ayman H Fanous; Yuli Li; Nallakkandi Rajeevan; Frederick Sayward; Krishnan Radhakrishnan; Grant Huang; Mihaela Aslan Journal: Pers Med Psychiatry Date: 2021-07